stockrow
Friday 6 November 2026
Export GUTS’s income statement to Excel — free account
Fractyl Health, Inc.
GUTS Healthcare Biotechnology
Fractyl Health, Inc.’s revenue for fiscal 2024 (year ended December 2024) was $93,000.00, down 22.5% from fiscal 2023.
- Revenue
- −57.1%
- EPS
- +71.9%
- Free cash flow
- +25.3%
- Total debt
- +1.54%
Quarter to June 2026, against a year earlier
0.94
0.04
+4.44%
Follow GUTS
Alert me
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| 1,063.04% | (778.33%) | (744.17%) | (518.40%) |
+8 more TTM periods Free account |
|
| (146.75%) | (118.41%) | (122.85%) | (101.33%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(295.82%) | (205.18%) | (196.71%) | (191.82%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(6.24) | (6.64) | (14.39) | (16.12) | |
Free Cash Flow |
(82.43) | (87.73) | (90.88) | (86.81) | |
Capital Expenditures |
— | — | (0.56) | (0.79) | |
| Other line items | |||||
Cash ROIC |
(108.57%) | (76.50%) | (74.75%) | (82.48%) | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.78 | 0.81 | 0.64 | 0.70 | |
Depreciation/Fixed assets |
0.61 | 0.53 | 0.47 | 0.40 | |
Capex/Depreciation |
0.00 | 0.00 | (0.49) | (0.73) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(6.24) | (6.64) | (14.30) | (15.97) | |
Capex per Share |
0.00 | 0.00 | (0.09) | (0.15) | |
Capex to Sales |
— | — | 0.00 | 0.00 |
Columns are period end dates · fundamentals updated 2 Nov 2026